More aggressive treatment warranted in patients with metabolic syndrome

September 05, 2006

More aggressive treatment with statins is necessary to lower LDL (low-density lipoprotein) cholesterol in patients with coronary heart disease and metabolic syndrome, a syndrome composing of three cardiovascular risk factors (see Editor's Notes) according to an Article published online today (Tuesday September 5, 2006) by The Lancet.

The Treating to New Targets (TNT) study was a prospective, double blind, parallel-group trial which was done at 256 sites in 14 countries between 1998 and 2004, with a median follow-up of 4.9 years. The analysis by Prakash Deedwania and colleagues (University of California, San Francisco, USA) involved 5584 patients with metabolic syndrome and clinically evident coronary heart disease aged 35--75 years.

The patients were randomly assigned to receive either atorvastatin 10mg per day or 80mg per day (aggressive treatment). At 3 months patients on 10mg per day had mean LDL cholesterol concentrations of 2.5mmol/L, compared with 1.9mmol/L in the aggressively treated patients. Major cardiovascular events occurred in 13% patients receiving atorvastatin 10mg, compared with 9.5% receiving 80mg. Irrespective of treatment, significantly more patients with metabolic syndrome (11.3%) had a major cardiovascular event than those without metabolic syndrome (8%). This increased risk was significantly reduced by intensive therapy with atorvastatin 80mg beyond that achieved with 10mg. The analysis suggests that the risk of major cardiovascular events increases with the presence of each component of the metabolic syndrome, and patients with diabetes also have a much higher risk.

By focusing aggressive statins therapy (80mg a day instead of 10mg a day) on patients with metabolic syndrome or diabetes in a population with stable coronary heart disease, allows the number needed to treat to be reduced significantly, which gains a significant improvement in the cost-effectiveness of high statin dose.
Notes to Editors: Metabolic Syndrome--Although there is some disagreement about the criteria for metabolic syndrome, it is generally described as the clustering of at least three cardiovascular risk factors, such as insulin resistance, obesity, large waist circumference, hypertension, and dyslipidiaemia*. The metabolic syndrome has been closely linked to diabetes and cardiovascular disease.

*Dislipidaemia--A disorder of lipoprotein metabolism, including lipoprotein overproduction or deficiency. Dyslipidaemia may be manifested by elevation of the total cholesterol, LDL cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood.

Professor Prakash C Deedwania, Professor of Medicine, University of California, San Francisco, VA Central California Healthcare System, 2615 E Clinton Avenue, Fresno CA 93703, USA. T) +93-4414177 (Hotel Milleni Apsis, Barcelona. From September 2 to 7)


Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to